skip to Main Content

New Therapeutics from Thüringen: A Gera-based biotech company is producing new compounds for clinical studies

  • 2018

The Thuringia Start-up Fund (TSF), which is man­aged by bm|t, has invested in BianoGMP for the pro­duc­tion of DNA and RNA based therapeutics.

There remain many preva­lent dis­eases with­out effec­tive treat­ments. Thank­fully, there is an abun­dance of small com­pa­nies and research groups work­ing on new com­pounds to address these dis­eases. In recent years there has been a research move­ment toward DNA and RNA based ther­a­peu­tics. How­ever, before these inno­v­a­tive com­pounds can be tested with patients in clin­i­cal stud­ies the qual­ity of the pro­duc­tion must be assured using GMP, or Good Man­u­fac­tur­ing Prac­tice, in indus­try parlance.

BianoGMP will act as an inno­v­a­tive small and mid-size batch pro­ducer for the com­pa­nies and researchers that are devel­op­ing these DNA and RNA based com­pounds, mak­ing the path to the clinic less ardu­ous,” stated Ste­fan Jahn, Invest­ment Man­ager at bm|t.

The BianoGMP team has been work­ing for many years with RNA ther­a­peu­tics and devel­oped a new class of patented com­pounds as part of a grant-funded project with Friedrich-Schiller Uni­ver­sity in Jena. “Our part­ner com­pany, BianoScience GmbH will be one of the first cus­tomers and ben­e­fi­cia­ries of BianoGMP´s pro­duc­tion ser­vices. Patients will also ben­e­fit from our ser­vices in that inno­v­a­tive ther­a­peu­tics will have a quicker devel­op­ment path,” said Dr. Tobias Pöhlmann, CEO from BianoGMP.

Dr. Rolf Gün­ther, Co-CEO from BianoGMP focused on the role of regional investors: “This invest­ment from bm|t, the MBG, and many pri­vate indi­vid­u­als from Thuringia will allow us to build a highly-chal­leng­ing and high-per­for­mance pro­duc­tion facil­ity in Gera. We will work with ther­a­peu­tic devel­op­ers to make their devel­op­ment work more effi­cient and the path to the clinic faster.”

About bm‑t

Erfurt-based, beteili­gungs­man­age­ment Thürin­gen (bm|t) – a sub­sidiary of the Thuringia Devel­op­ment Bank, is the first address for invest­ments in Thuringia, Ger­many. bm‑t cur­rently man­ages eight invest­ment funds with a total vol­ume of 320M EUR. bm‑t invests in inno­v­a­tive com­pa­nies with strong growth poten­tial across all sec­tors and all phases of the cor­po­rate lifecycle.

About MBG

The MBG mbH has been estab­lished in Thuringia for 25 years. With over 100 invest­ments in its port­fo­lio, the MBG is a major sup­porter of com­pany for­ma­tion, estab­lished enter­prises, and suc­ces­sion plan­ning in Thuringia.

About Biano GMP

BianoGMP was founded in August 2017 with the aim of being a GMP ser­vice provider for small to medium batch sizes in the field of oligonu­cleotides. By offer­ing out­sourced small and medium sized batch pro­duc­tion, BianoGMP will allow early-stage biotech com­pa­nies to reduce costs and shorten their devel­op­ment time­lines. The com­pany is also devel­op­ing meth­ods to offer a wide-range of oligo devel­op­ment and pro­duc­tion capabilities.

Press Contacts

BianoGMP GmbH
Dr. Tobias Pöhlmann und Dr. Rolf Günther
Ron­neb­urger Straße 74
07546 Gera

Tel: +49 365 77347180
Email:
www.BianoGMP.com

bm‑t beteili­gungs­man­age­ment thürin­gen gmbh
Ste­fan Jahn und Katrin Uschmann
Gork­istraße 9
99084 Erfurt

Tel: +49 361 7447 601
Fax: +49 361 7447 635

Back To Top
×Close search
Search